Phase III trial comparing administration of alvocidib given in timed-sequential-therapy with cytarabine and mitoxantrone with cytarabine and mitoxantrone alone in patients with acute myeloid leukaemia

Trial Profile

Phase III trial comparing administration of alvocidib given in timed-sequential-therapy with cytarabine and mitoxantrone with cytarabine and mitoxantrone alone in patients with acute myeloid leukaemia

Planning
Phase of Trial: Phase III

Latest Information Update: 26 Jan 2017

At a glance

  • Drugs Alvocidib (Primary) ; Cytarabine; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Tolero Pharmaceuticals
  • Most Recent Events

    • 26 Jan 2017 This trial was being conducted by Tolero Pharmaceuticals. The Company has now been acquired by Sumitomo Dainippon Pharma, according to a Sumitomo Dainippon Pharma media release.
    • 09 Nov 2015 According to a Tolero Pharmaceuticals media release, after an end of phase II meeting with US FDA , 'rate of complete remission' was confirmed as the primary endpoint of this study.
    • 27 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top